{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-23-000041","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.921175+00:00","generated_at":"2026-06-08T08:30:25.477306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharma Q3 revenue $131.8M (+57% YoY); raises FY2023 guidance","bullets":["Record Q3 net revenue $131.8M, up 57.3% YoY; GAAP net income $9.5M ($0.45 diluted EPS).","Adjusted non-GAAP EBITDA $36.5M (+98% YoY); adj. diluted EPS $1.27 vs $0.58 YoY.","Cortrophin Gel net sales $29.7M (+136% YoY); full-year Cortrophin guidance raised to $100M-$107M.","FY2023 revenue guidance raised to $468M-$478M (prev. $425M-$445M); adj. EPS guided $4.29-$4.57.","Generics/Established Brands revenue $102.1M (+43.4% YoY); 5 new products launched in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-23-000041","json":"https://secwatch.observer/filing/0001023024-23-000041.json","markdown":"https://secwatch.observer/filing/0001023024-23-000041.md","text":"https://secwatch.observer/filing/0001023024-23-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/0001023024-23-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/ani-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:30:25.477306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fb6640dacf9ebea6e5792fcd1e48be86901c79b","claim":"ANI PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue $131.8 million, net income $9.5 million, EPS $0.45. Guidance raised.","evidence_excerpt":"Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/0001023024-23-000041-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$131.8 million"},{"label":"Net income","value":"$9.5 million"},{"label":"EPS","value":"$0.45"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}